

09 May 2022 | Interviews

Over The Counter 9 May 2022: The Landscape Of Naloxone Access With HRT's **Michael Hufford**

by Hannah Daniel

In this episode, HBW Insight speaks to Michael Hufford, co-founder and CEO of Harm Reduction Therapeutics about the inaccessibility in the US of naloxone, a life-saving opioid overdose antidote. Hufford unpacks the history of naloxone access and explains why standing orders aren't as helpful as they seem. We also explore the incentives for companies currently producing prescription naloxone to make the switch to OTC status, and why many of them have chosen not to. While the financial incentive may not be there, the public health need is dire, and Hufford explains the importance of harm reduction groups and non-profit pharmaceutical companies for getting naloxone into the hands of those who need it the most.

Click here to explore this interactive content online



Further Reading

HRT Reports 'Remarkable Achievement' In OTC Naloxone Phase 1 Clinical Trial Results

OTC Naloxone May Get Another Push From US FDA As Agency Prepar es Novel Switch Proposed Rule

Drivers For Allowing OTC Naloxone In US Include Social Justice As Well As Public Health Need

OTC Naloxone Nasal Spray Biocompatibility Study Funded In US From Purdue Pharma Bankruptcy

FDA Has Model Drug Facts Labels For OTC Naloxone, Wants Switch Proposals



Further Listening

Check out this episode of the Pink Sheet Podcast, where Pink Sheet and HBW Insight reporters and editors discuss comments that FDA commissioner Robert Califf made implying that the FDA might step in to urge manufacturers to pursue an Rx-to-OTC switch of naloxone.

Click here to explore this interactive content online



These and all other podcasts are available on the Informa Pharma Intelligence channel on *Apple* Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Over The Counter Theme Music:

Modern Chillout by penguinmusic

Copyright 2021 Licensed under a commercial Pixabay License.